78. 下垂体前葉機能低下症 [臨床試験数:462,薬物数:346(DrugBank:45),標的遺伝子数:41,標的パスウェイ数:80

Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02360046
(ClinicalTrials.gov)
January 201516/1/2015The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic HypopituitarismThe Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids (Intrahepatocellular IHCL and Intramyocellular IMCL) in Patients With Corticotropic Hypopituitarism, a Randomised Placebo-controlled Double-blind TrialHypopituitarism;Hydrocortisone;Lipids;Fatty Acids, Nonesterified;Insulin SensitivityDrug: Hydrocortisone;Drug: PlaceboUniversity Hospital Inselspital, BerneNULLTerminated18 YearsN/AAll30N/ASwitzerland
2EUCTR2014-002039-32-DK
(EUCTR)
02/09/201407/07/2014Fatigue in patients with adrenal insufficiency - a comparison of the effect of a new modified-release hydrocortisone, and conventional hydrocortisone.PlenadrEMA study - Effect of modified-release compared to conventional hydrocortisone on fatigue, measured by Ecological Momentary Assessments; a pilot study to assess feasibility, responsiveness of outcomes and to inform power calculations for future large-scale RCTs - PlenadrEMA study Secondary adrenal insufficiency due to hypopituitarism
MedDRA version: 20.0;Level: LLT;Classification code 10052382;Term: Secondary adrenal insufficiency;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Plenadren 5 mg modified-release tablets
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE
Trade Name: Hydrocortisone TAKEDA, tabletter
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE
Product Name: Hydrokortison Glostrup 5 mg
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE
Trade Name: Plenadren 20 mg modified-release tablets
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE
Rigshospitalet, Copenhagen University HospitalNULLNot RecruitingFemale: yes
Male: yes
30Phase 4Denmark
3NCT01804413
(ClinicalTrials.gov)
March 201118/2/2013Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone DeficiencyEffects of Pegvisomant-Priming With the Glucagon Stimulation Test in Assessing GH and Cortisol Reserve in Adults: a Randomized Proof-of-Concept Pilot StudyAdults Growth Hormone Deficiency.Drug: Pegvisomant;Drug: Regular insulinOregon Health and Science UniversityAarhus University HospitalRecruiting21 Years55 YearsBoth10N/AUnited States
4EUCTR2009-010918-30-IE
(EUCTR)
11/08/200911/03/2009Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care.
MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism
MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism
MedDRA version: 9.1;Classification code 10056438;Term: Growth hormone deficiency
MedDRA version: 9.1;Classification code 10011318;Term: Craniopharyngioma
MedDRA version: 9.1;Classification code 10036832;Term: Prolactinoma
MedDRA version: 9.1;Classification code 10011651;Term: Cushing's disease
MedDRA version: 9.1;Classification code 10035104;Term: Pituitary tumour
MedDRA version: 9.1;Classification code 10061538;Term: Pituitary tumour benign
Trade Name: Genotropin 5.3mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin 12mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.4mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.6mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.8mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.0mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniqu
Amar Agha, Beaumont HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Ireland
5NCT00851942
(ClinicalTrials.gov)
September 200825/2/2009Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen TestDetermination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen TestHealthy;Adrenal Insufficiency;HypopituitarismDrug: Synacthen (Tetracosactrin)Cardiff UniversityNULLCompleted18 Years80 YearsAll165Phase 4United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-000056-14-GB
(EUCTR)
03/03/200804/01/2008Determination of method-specific normal cortisol and adrenal hormone responses to the short Synacthen test - Short Synacthen test StudyDetermination of method-specific normal cortisol and adrenal hormone responses to the short Synacthen test - Short Synacthen test Study Normal, healthy volunteers to establish a reference range for the synacthen test, plus patients with hypoadrenalism/hypopituitarism
MedDRA version: 9.1;Level: LLT;Classification code 10020936;Term: Hypoadrenalism
MedDRA version: 9.1;Classification code 10021067;Term: Hypopituitarism
Cardiff UniversityNULLNot Recruiting Female: yes
Male: yes
240 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
7EUCTR2007-005018-37-IE
(EUCTR)
18/01/200807/09/2007Optimal glucocorticoid replacement therapy in adrenocorticotropin (ACTH) deficient hypopituitary patients - Optimal glucocorticoid replacementOptimal glucocorticoid replacement therapy in adrenocorticotropin (ACTH) deficient hypopituitary patients - Optimal glucocorticoid replacement 10 male patients with hypopituitarism resulting in ACTH (adrenocorticotropin) deficiency (ICD E23.0) will be studied on varying doses of hydrocortisone replacement therapy. THis is not a new medication for these patients.10 healthy male volunteers will be studied as control subjects. They will NOT receive hydrocortisone.
MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism
MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism
MedDRA version: 9.1;Classification code 10057217;Term: Isolated ACTH deficiency
Trade Name: Hydrocortone
INN or Proposed INN: Hydrocortisone
INN or Proposed INN: Hydrocortisone
Amar AghaNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
20Ireland
8NCT00517062
(ClinicalTrials.gov)
January 200615/8/2007Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production RatesEffects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient AdultsGrowth Hormone DeficiencyDrug: Growth hormone (Genotropin);Drug: PlaceboOregon Health and Science UniversityNULLCompleted18 Years75 YearsBoth16Phase 0United States
9NCT00139945
(ClinicalTrials.gov)
October 200530/8/2005Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient PatientsEffects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol InteractionHypopituitarismDrug: Human acylated ghrelinUniversity of AarhusNULLCompleted18 Years60 YearsBoth8N/ADenmark